22.7 C
New York
Monday, June 8, 2026

Tag: Entrepreneurship

Beyond the Aisles: The Food Purveyor’s Inspirational Impact on Malaysian Retail

SINGAPORE, July 21, 2025 /PRNewswire/ -- The Food Purveyor, a leading Malaysian grocer, has demonstrated remarkable success through its strategic multi-brand approach, operating Village...

Taste the Future: Savourés Group Awarded for Its Agile Culture and Next-Generation Food Solutions

SINGAPORE, July 17, 2025 /PRNewswire/ -- Savourés Group is rapidly emerging as a powerhouse in the specialty food ingredient (SFI) sector, pioneering a unique...

Fourth TERA-Award Ceremony held in Cambridge

4th TERA-Award in Cambridge celebrates clean energy winners. Innovative smart solutions set to transform the energy sector.

Presentation Analyzes Elon Musk’s Next Potential Move — Points to August 13 as a Key Date

Tech Expert and Former Hedge Fund Manager James Altucher Releases Detailed Brief Uncovering Three Overlooked Clues Surrounding Starlink and a Potential Public Event
Tech Expert and Former Hedge Fund Manager James Altucher Releases Detailed Brief Uncovering Three Overlooked Clues Surrounding Starlink and a Potential Public Event

Robert J. Smith, MFA’s First Release in His INFLUENCE IN ACTION™ Book Series Tops legends, W. Edwards Deming, Edward Bernays and Adam Smith

WINTER GARDEN, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Smith Profits™, in association with Junior Patriots, a 501c(3) nonprofit organization, announces that its founder, Robert J. Smith, MFA, The Father of Factual Storytelling’s latest release, INFLUENCE IN ACTION™ GAINS PROVEN RESULTS AND DRIVES SALES is an International #1 Best Seller.

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

Astellas Announces a Partnership with the “Korea Institute of Startup and Entrepreneurship Development”, an Umbrella Organization of the “Ministry of SMEs and Startups”, a...

- Supporting Korean Startups' Drug Discovery Research and Global Expansion - - First Pharmaceutical Company from Japan to Actively Support the Operation of the Program...

Testele UE privind jucăriile pentru activități destinate copiilor arată o gamă largă de deficiențe

BRUXELLES, July 16, 2025 (GLOBE NEWSWIRE) -- O proporție semnificativă a jucăriilor pentru activități destinate copiilor comercializate în UE nu respectă standardele UE, potrivit unor teste efectuate pe un eșantion de 89 de leagăne, turnuri de activități și cadre de cățărat. Acesta este rezultatul unei campanii de inspecție, JACOP 2024, organizate de Direcția Generală Piață Internă, Industrie, Antreprenoriat și IMM-uri (DG GROW) a Comisiei Europene.

Las pruebas de la UE sobre juguetes de actividad para niños revelan numerosos fallos

BRUSELAS, July 16, 2025 (GLOBE NEWSWIRE) -- Una parte importante de los juguetes de actividad para niños vendidos en la UE incumple las normas europeas, como demuestran las pruebas realizadas en una muestra de 89 columpios, torres de actividades y juguetes para trepar. Este es el resultado de una campaña de inspección, las JACOP 2024, organizada por la Dirección General de Mercado Interior, Industria, Emprendimiento y Pymes (DG GROW) de la Comisión Europea.

EU-Prüfungen zu Aktivitätsspielzeug für Kinder zeigen weitreichende Mängel

BRÜSSEL, July 16, 2025 (GLOBE NEWSWIRE) -- Ein erheblicher Anteil der in der EU verkauften Aktivitätsspielzeuge für Kinder entspricht nicht den EU-Normen, wie Prüfungen an einer Stichprobe von 89 Schaukeln, Aktivitätstürmen und Kletterspielzeug für den Innenbereich gezeigt haben. Das ist das Ergebnis der Prüfkampagne JACOP 2024, die von der Generaldirektion Binnenmarkt, Industrie, Unternehmertum und KMU der Europäischen Kommission (GD GROW) organisiert wurde.

Cognition AI Acquires Windsurf—Evaluating Strategic Implications in A.I. Investment

Cognition AI, an artificial intelligence start-up specializing in software coding assistance, strategically acquired rival Windsurf, furthering the competitive landscape in AI technology. This acquisition...

The Human Capability Initiative (HCI) Launches the 2025 Insight Report

RIYADH, Saudi Arabia, July 15, 2025 /PRNewswire/ -- The Human Capability Development Program (HCDP) - one of the Saudi Vision 2030 Realization Programs –...

Impact Capital Managers Association Announces Five New Board Members

The directors reflect ICM's expanding network of private capital funds investing for superior returns and meaningful impact NEW YORK, July 15, 2025 /PRNewswire/ -- Impact...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsEntrepreneurship